Business Description
Compass Therapeutics Inc
NAICS : 541714
SIC : 2834
80 Guest Street, Suite 601, Boston, MA, USA, 02135
Description
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.77 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -23.3 | |||||
| 3-Year EPS without NRI Growth Rate | -27.9 | |||||
| 3-Year FCF Growth Rate | 21 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.32 | |||||
| 9-Day RSI | 53.28 | |||||
| 14-Day RSI | 51.56 | |||||
| 6-1 Month Momentum % | 43.69 | |||||
| 12-1 Month Momentum % | -40.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.36 | |||||
| Quick Ratio | 12.36 | |||||
| Cash Ratio | 12.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.6 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -38.1 | |||||
| ROA % | -33.52 | |||||
| ROIC % | -348.98 | |||||
| ROC (Joel Greenblatt) % | -555.17 | |||||
| ROCE % | -36.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.15 | |||||
| Price-to-Tangible-Book | 2.13 | |||||
| EV-to-EBIT | -4.13 | |||||
| EV-to-Forward-EBIT | -4.01 | |||||
| EV-to-EBITDA | -4.35 | |||||
| EV-to-Forward-EBITDA | -4.01 | |||||
| EV-to-FCF | -6.47 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 2.27 | |||||
| Earnings Yield (Greenblatt) % | -24.27 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CMPX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.3 | ||
| Beta | 0 | ||
| Volatility % | 130.41 | ||
| 14-Day RSI | 51.56 | ||
| 14-Day ATR ($) | 0.188548 | ||
| 20-Day SMA ($) | 2.654 | ||
| 12-1 Month Momentum % | -40.11 | ||
| 52-Week Range ($) | 1.25 - 4.6 | ||
| Shares Outstanding (Mil) | 101.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Compass Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||